Advantages and applications of CAR-expressing natural killer cells
Open Access
- 12 February 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 6, 21
- https://doi.org/10.3389/fphar.2015.00021
Abstract
In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against resistant cancer cells, auspicious efforts have been made with chimeric antigen receptor (CAR) expressing T- and NK cells. These CAR-modified cells express antigen receptors against tumor-associated surface antigens, thus redirecting the effector cells and enhancing tumor-specific immunosurveillance. However, many cancer antigens are also expressed on healthy tissues, potentially leading to off tumor/ on target toxicity by CAR-engineered cells. In order to control such potentially severe side effects, the insertion of suicide genes into CAR-modified effectors can provide a means for efficient depletion of these cells. While CAR-expressing T cells have entered successfully clinical trials, experience with CAR-engineered NK cells is mainly restricted to pre-clinical investigations and predominantly to NK cell lines. In this review we summarize the data on CAR expressing NK cells focusing on the possible advantage using these short-lived effector cells and discuss the necessity of suicide switches. Furthermore, we address the compliance of such modified NK cells with regulatory requirements as a new field in cellular immunotherapy.Keywords
This publication has 80 references indexed in Scilit:
- Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing ProtocolFrontiers in Oncology, 2013
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive ImmunotherapyMolecular Therapy, 2010
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical TrialMolecular Therapy, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cellsLeukemia Research, 2009
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral methodCancer Gene Therapy, 2009
- Graft-versus-host diseaseThe Lancet, 2009